Biogen Idec Inc (BIIB): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Biogen Idec ( BIIB) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.2%. By the end of trading, Biogen Idec fell $4.72 (-1.6%) to $286.18 on average volume. Throughout the day, 1,129,263 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,200,200 shares. The stock ranged in price between $284.70-$293.20 after having opened the day at $292.99 as compared to the previous trading day's close of $290.90. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 42.4%, Curis ( CRIS), down 18.7%, Array BioPharma ( ARRY), down 12.5% and Conatus Pharmaceuticals ( CNAT), down 7.8%.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $67.3 billion and is part of the health care sector. The company has a P/E ratio of 40.0, above the S&P 500 P/E ratio of 17.7. Shares are up 94.7% year to date as of the close of trading on Friday. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Hemispherx Biopharma ( HEB), up 60.0%, Prana Biotechnology ( PRAN), up 16.5%, Atossa Genetics ( ATOS), up 14.7% and Coronado Biosciences ( CNDO), up 13.4% , were all gainers within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC